Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Nascent Announces the Completion of Its Phase1 Clinical Trials

NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Company has completed and closed its Phase I clinical trial evaluating safety and tolerance for Pritumumab ("PTB") as a treatment for Primary and Metastatic Brain Cancers. Previous announcements shared the end of the enrollment and dosing period of the Phase I trial.

Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration.

Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. Phase I reinforced the companies' determination and excitement around this unique monoclonal antibody treatment approach and Phase I has shown that it can be given safely at high doses. This is a new pathway toward attacking one of the defining health challenges we face, with longer-term implications that transcend the brain cancer market. We look forward to the opportunity to see our unique R&D platform become a game changer for patients suffering from brain cancer.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | CEO | Nascent Biotech, Inc.
sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.



View source version on accesswire.com:
https://www.accesswire.com/741102/Nascent-Announces-the-Completion-of-Its-Phase1-Clinical-Trials

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.